Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07025330 · ClinicalTrials.gov registry record · Phase 2
A Study of Efgartigimod in Patients With IgG4-Related Disease
A Phase 2 study of IgG4 Related Disease, sponsored by Stanford University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT07025330: Recruiting Phase 2 study of IgG4 Related Disease, sponsored by Stanford University.
NCT07025330 is a Phase 2 study of IgG4 Related Disease that is actively recruiting participants, run by Stanford University. The registered enrollment target is 5 participants, below the 91-participant average among 4 other IgG4 Related Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07025330, a Phase 2 study of IgG4 Related Disease, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if efgartigimod can treat IgG4-related disease in adults. The main questions it aims to answer are: In patients with IgG4-related disease, does treatment with efgartigimod reduce the volume of the: * lacrimal gland(s) and/or * salivary gland(s) and/or * pancreas Participants will: * Receive efgartigimod once weekly for up to 12 weeks * Visit the clinic every one to six weeks for checkups and tests * Be asked to complete questionnaires to see how they feel on efgartigimod
Conditions Studied
Interventions
- DRUG Efgartigimod
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2025-11-12 |
| Est. Completion | 2028-06-01 |
| Phase | Phase 2 |
What NCT07025330 shows while recruiting
NCT07025330 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 91-participant average among 4 other IgG4 Related Disease trials with a reported enrollment target (95% lower).
The record links to 1 condition, with IgG4 Related Disease appearing as the primary indexed condition, and to 1 intervention - of which Efgartigimod is the first listed.
NCT07025330 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07025330 about?
NCT07025330 is a clinical study titled "A Study of Efgartigimod in Patients With IgG4-Related Disease". The goal of this clinical trial is to learn if efgartigimod can treat IgG4-related disease in adults. The main questions it aims to answer are: In patients with IgG4-related disease, does treatment with efgartigimod reduce the volume of the: * lacrimal gland(s) and/or * salivary gland(s) and/or * ...
What is the current status of trial NCT07025330?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2025-11-12. Estimated completion is 2028-06-01.
What conditions does trial NCT07025330 study?
This clinical trial studies the following conditions: IgG4 Related Disease.
What interventions are being tested in trial NCT07025330?
The interventions under investigation include: Efgartigimod (DRUG).
Who is sponsoring clinical trial NCT07025330?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07025330 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IgG4 Related Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
RECRUITING · Phase 1
-
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
ACTIVE NOT RECRUITING · Phase 3
-
Treatment of IgG4-Related Disease With Revlimid and Rituximab
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI